NCT04807595: Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: HER2-low
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received a metastatic breast cancer diagnosis between 01 January 2015 and 31 December 2017; Patients must have been diagnosed as HER2-negative with an IHC of 0, 1+, 2+ and ISH negative; Patient must have progressed on any systemic anti-cancer therapy in the metastatic setting
Exclusions: Patients with HER2+ breast cancer (e.g. IHC 3+) or HER2-negative with an IHC of 2+ and ISH positive

Comments are closed.

Up ↑